Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.54 |
| ▸ | RXRB | P28702 | 5/20 | 0.54 |
| ▸ | RXRG | P48443 | 5/20 | 0.54 |
| ▸ | CYP26B1 | Q9NR63 | 8/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.51 |
| ▸ | RARA | P10276 | 2/20 | 0.46 |
| ▸ | RARB | P10826 | 2/20 | 0.46 |
| ▸ | RARG | P13631 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897524 | 0.84 | CYP26B1 (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL3546404 | 0.82 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL1616186 | 0.82 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL2312146 | 0.82 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL2095481 | 0.82 | RXRA (0.57) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL14286073 | 0.82 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL694638 | 0.82 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL12743622 | 0.82 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL6909472 | 0.81 | CYP26B1 (0.50) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL9770732 | 0.80 | ESR2 (0.38) | RXRARXRBRXRGCYP26B1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11637257-B2 | Electroluminescent material ink and electroluminescent device thereof | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO. LTD (CN) | 2023-04-25 | — | — | US | claimed |
| CN-109929328-B | Composite ink and preparation method and device thereof | TCL科技集团股份有限公司 | 2021-10-22 | — | — | CN | claimed |
| US-20200373508-A1 | ELECTROLUMINESCENT MATERIAL INK AND ELECTROLUMINESCENT DEVICE THEREOF | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) | 2020-11-26 | — | — | US | claimed |
| CN-108948865-B | Electroluminescent material ink and electroluminescent device thereof | 广东聚华印刷显示技术有限公司 | 2020-07-10 | — | — | CN | claimed |
| CN-109929328-A | A kind of compound ink and preparation method thereof, device | TCL集团股份有限公司 | 2019-06-25 | — | — | CN | claimed |
| US-11637257-B2 | Electroluminescent material ink and electroluminescent device thereof | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO. LTD (CN) | 2023-04-25 | — | — | US | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| CN-109929328-B | Composite ink and preparation method and device thereof | TCL科技集团股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20200373508-A1 | ELECTROLUMINESCENT MATERIAL INK AND ELECTROLUMINESCENT DEVICE THEREOF | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHYNKX THERAPEUTICS, LLC | 2020-10-01 | — | — | US | disclosed |
| CN-108948865-B | Electroluminescent material ink and electroluminescent device thereof | 广东聚华印刷显示技术有限公司 | 2020-07-10 | — | — | CN | disclosed |
| CN-109929328-A | A kind of compound ink and preparation method thereof, device | TCL集团股份有限公司 | 2019-06-25 | — | — | CN | disclosed |
| US-5149705-A | Treatment of psoriasis | ALLERGAN, INC. (US) | 1992-09-22 | — | — | US | disclosed |
| EP-0294746-A1 | Bicyclic nitro compounds | L. GIVAUDAN & CIE Société Anonyme (CH) | 1988-12-14 | — | — | EP | disclosed |
| EP-0284261-A1 | Acetylenes disubstituted with a heteroaromatic group and a tetralin group having retinoid like activity | ALLERGAN, INC (US) | 1988-09-28 | — | — | EP | disclosed |
| CN-88101234-A | Acetylenes disubstituted with heteroaryl and tetralinyl having retinoid-like activity | — | 1988-09-28 | — | — | CN | disclosed |
| EP-0040338-A2 | Process for the preparation of acylated indanes and tetrahydronaphthalenes | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-11-25 | — | — | EP | disclosed |
| US-4178311-A | Process for the production of compounds useful in perfumery | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1979-12-11 | — | — | US | disclosed |
| EP-0004914-A1 | Process for the production of compounds useful in perfumery | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1979-10-31 | — | — | EP | disclosed |
| US-4162256-A | Process for the production of compounds useful in perfumery | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1979-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | RXRA 4349/4885RXRB 4100/4885RXRG 4421/4885 |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | RXRA 4349/4885RXRB 4100/4885RXRG 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.